Natera is the industry growth leader in diagnostics with 39% revenue growth year-over-year, FCF-positive despite GAAP losses, and a Rule of 40 score of 44, but faces three consecutive earnings misses and a low asymmetry ratio at current price levels, making the thesis dependent on growth rate sustainability.
Thesis pillars
- Fcf Positive Despite Gaap Losses→Stable
- Industry Leading Revenue Growth→Stable
- Consecutive Earnings Misses→Stable
- +1 more pillar — see the Why tab for full reasoning
Natera, Inc. (NTRA) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Analyst target reached at $279.32 — A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.1% away).
Natera applies cell-free DNA technology to diagnostics across oncology, women's health, and organ health. The company generated $2,306.1 million in revenue in 2025, processing about 3.5 million tests, with most revenues from Panorama NIPT, Horizon carrier screening, and... Read more
Sell if holding. Analyst target reached at $279.32 — A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.1% away). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.80, earnings proximity 34d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Natera, Inc.
About Natera, Inc.
Natera generated $2,306.1 million in revenue in 2025, up from $1,696.9 million in 2024, with a net loss of $208.2 million and an accumulated deficit of $2.8 billion at December 31, 2025. The significant majority of revenues derives from three products: Panorama non-invasive prenatal testing, Horizon carrier screening, and Signatera tumor-informed circulating tumor DNA testing. The company processed approximately 3.5 million tests in 2025, up from 3.1 million in 2024.
Natera earns revenue from laboratory testing services billed to commercial insurance, Medicare, and Medicaid payers. Panorama—launched in 2013 and now the market leader by volume in the United States for NIPT—screens for fetal chromosomal abnormalities from a maternal blood draw as early as nine weeks of pregnancy. Signatera is custom-designed per patient from tumor tissue to track circulating tumor DNA; it holds Medicare coverage across colorectal, bladder, breast, and ovarian cancer as well as non-small cell lung cancer surveillance, and carries Breakthrough Device Designation from the FDA. Horizon carrier screening covers up to 835 inherited conditions. Illumina supplies the sequencers and reagents required for test processing; the 10-K discloses Illumina as both a key supplier and a NIPT competitor through its subsidiary Verinata Health. Bioinformatics algorithms run primarily on the DNAnexus platform hosted on AWS, with no backup cloud platform disclosed.
Show full overview
The supplier-competitor overlap with Illumina poses a compounding risk: if Illumina restricts access to sequencing instruments or raises prices, Natera's test volumes could stall. The 10-K also notes that transitioning sequencing platforms could expose the company to claims of infringement of Illumina intellectual property rights, limiting practical substitutability. Separately, the DNAnexus platform hosts the majority of Natera's proprietary algorithms; any termination of that agreement would interrupt algorithmic processing for both internal labs and Constellation licensees, for which the company acknowledges no backup cloud platform exists.
See also: Healthcare · Diagnostics & Research
From Natera, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-07-06Recent Developments — Natera, Inc.
Latest news
- NEWS Natera shares slide as investors weigh near-term sentiment headwinds ahead of upcoming earnings - Quiver Quantitative — Quiver Quantitative negative
- NEWS Natera, Inc. (NASDAQ:NTRA) Short Interest Down 22.5% in April - MarketBeat — MarketBeat negative
- NEWS Should You Be Bullish on Natera (NTRA)? - Yahoo Finance — Yahoo Finance positive
- NEWS What To Expect From Natera’s (NTRA) Q4 Earnings - StockStory — StockStory neutral
- NEWS Natera president John Fesko sells $59,992 of NTRA shares - Investing.com — Investing.com negative
Generated 2026-07-06T06:50:34Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $279.32 — A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.1% away). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $259.77. Score 5.3/10, moderate confidence.
Take-profit target: $274.04 (-1.9% upside). Prior stop was $259.77. Stop-loss: $259.77.
Analyst target reached - limited upside remaining; Near 52-week high (0.1% away); Consecutive earnings misses (3).
Natera, Inc. trades at a P/E of N/A (forward -1309.8). TrendMatrix value score: 1.8/10. Verdict: Sell.
27 analysts cover NTRA with a consensus score of 4.3/5. Average price target: $265.
What does Natera, Inc. do?Natera applies cell-free DNA technology to diagnostics across oncology, women's health, and organ health. The company...
Natera applies cell-free DNA technology to diagnostics across oncology, women's health, and organ health. The company generated $2,306.1 million in revenue in 2025, processing about 3.5 million tests, with most revenues from Panorama NIPT, Horizon carrier screening, and Signatera MRD tests. CLIA-certified labs operate in Texas, California, and Colorado, with over 100 global laboratory and distribution partners.